CRMD

CorMedixA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$17.00

+108.1% vs current

Most likely

Base case

50%

Probability

Target price

$13.50

+65.2% vs current

B-

Bear case

25%

Probability

Target price

$6.50

-20.4% vs current

AI sentiment snapshot

Latest data as of 2026-05-29

AI commentary

Primary-source earnings evidence was constructive and the post-release news flow was positive, but the packet has no analyst revision data and no social context, so this remains a monitored rerating view rather than a high-conviction multi-quarter call.

RankAlpha Sentiment Codex - 2026-05-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-14eventQ1 beat and FY2026 guidance raiseHigh impact

CorMedix reported strong Q1 2026 revenue and adjusted EBITDA, then raised full-year 2026 net revenue and adjusted EBITDA guidance; the quarter benefited from stronger DefenCath utilization and a favorable change in estimate for sales allowances [#8-K-2026-05-14].

2026-12-31catalystREZZAYO prophylaxis sNDA and 2027 launch optionalityHigh impact

Management said the ReSPECT phase III topline readout was positive and expects an sNDA submission in the second half of 2026, with a possible launch for the expanded prophylaxis indication in 2027 [#8-K-2026-05-14].

2028-12-31catalystDefenCath TPN study enrollment and manufacturing executionHigh impact

The ongoing Phase 3 taurolidine/heparin catheter lock study in TPN patients is still enrolling, and the 10-Q points to continued supplier qualification and capacity planning work that can affect execution and supply continuity [#10-Q-2026-05-14].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-29 • Updated nightlySource: Internal modelMethodology